

DEFINITIONS

In this document, unless the context otherwise requires, the following terms shall have the meanings set out below.

“Accountants’ Report”	the accountants’ report on the historical financial information of our Company for the Track Record Period, the text of which is set out in Appendix I to this document
“affiliate”	any other person, directly or indirectly, controlling or controlled by or under direct or indirect common control with such specified person
“AFRC”	Accounting and Financial Reporting Council (會計和財務匯報局)
“Articles” or “Articles of Association”	the Articles of Association of our Company, as amended, which shall become effective on the [REDACTED], a summary of which is set out in Appendix V
“associate(s)”	has the meaning ascribed thereto under the Hong Kong Listing Rules
“Audit Committee”	the audit committee of the Board
“Board” or “Board of Directors”	the board of directors of our Company
“business day”	any day (other than a Saturday, Sunday or public holiday) on which banks in Hong Kong are generally open for business
“CAGR”	compound annual growth rate

[REDACTED]

“CG Code”	the Corporate Governance Code as set out in Appendix C1 to the Hong Kong Listing Rules
“Chifeng Mingquan”	Chifeng Mingquan Enterprise Management Center (Limited Partnership)* (赤峰名泉企業管理中心(有限合夥)), a limited partnership established in the PRC on March 17, 2022, one of our employee incentive platforms and one of the Controlling shareholders of the Company

DEFINITIONS

“Chifeng Qingxi”	Chifeng Qingxi Enterprise Management Center (Limited Partnership)* (赤峰清溪企業管理中心(有限合夥)), a limited partnership established in the PRC on March 12, 2020, one of our employee incentive platforms and one of the Controlling shareholders of the Company
“Chifeng Saliont”	Chifeng Saliont Pharmaceutical Co., Ltd.* (赤峰賽林泰藥業有限公司), formerly known as Chifeng Rongjitang Pharmaceutical Co., Ltd. (赤峰榮濟堂藥業有限公司), a limited liability company established in the PRC on June 11, 2004, and is owned by Mr. Li and his brother as to 97.41% and 2.59%, respectively as at the Latest Practicable Date
“China”, “Chinese mainland” or “PRC”	the People’s Republic of China, but for the purposes of this document and for geographical reference only, references in this document to “China”, “Chinese mainland” and/or the “PRC” do not apply to Hong Kong, the Macau Special Administrative Region and Taiwan (except where the context requires otherwise)
“CNIPA”	China National Intellectual Property Administration (國家知識產權局)
“Companies Ordinance”	the Companies Ordinance (Chapter 622 of the Laws of Hong Kong), as amended or supplemented or otherwise modified from time to time
“Companies (Winding Up and Miscellaneous Provisions) Ordinance”	the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Chapter 32 of the Laws of Hong Kong), as amended or supplemented or otherwise modified from time to time
“Company”, “our Company”, “we”, “our” or “us”	PrimeGenX Therapeutics Co., Ltd. (北京普祺醫藥科技股份有限公司), a limited liability company established in the PRC on September 26, 2016 and subsequently converted into a joint stock company with limited liability on April 25, 2022
“Controlling Shareholder(s)”	refers to Mr. Li, Chifeng Mingquan and Chifeng Qingxi, the controlling shareholders of our Company. See “Relationship with our Controlling Shareholders”
“Converted H Shares”	H Shares which will be converted from Domestic Shares immediately upon [REDACTED]
“Core Product”	has the meaning ascribed thereto in Chapter 18A of the Listing Rules; for the purpose of this document, our Core Product refers to PG-011 (Pumecitinib)
“CSDC”	China Securities Depository and Clearing Corporation Limited (中國證券登記結算有限責任公司)

DEFINITIONS

“CSRC”	the China Securities Regulatory Commission (中國證券監督管理委員會)
“Director(s)”	the director(s) of our Company
“Domestic Share(s)”	ordinary share in our capital, with a nominal value of RMB0.5 each, which are subscribed for and paid up in Renminbi
“Dr. Du”	Dr. Daniel Yunlong Du, an executive Director, deputy general manager and chief medical officer of our Company
“Dr. Han”	Dr. Han Yongxin (韓永信), the non-executive Director of our Company
“EIT”	enterprise income tax
“EIT Law”	the PRC Enterprise Income Tax Law (《中華人民共和國企業所得稅法》)
“ESG”	environmental, social and governance
“Extreme Conditions”	extreme conditions caused by a super typhoon or other natural disaster of a substantial scale seriously affects the working public’s ability to resume work or brings safety concern for a prolonged period as announced by the government of Hong Kong

[REDACTED]

“Frost & Sullivan”	Frost & Sullivan (Beijing) Inc., Shanghai Branch Co., the independent industry consultant commissioned by our Company to prepare the Frost & Sullivan Report
“Frost & Sullivan Report”	the independent research report commissioned by our Company and prepared by Frost & Sullivan
“General Rules of HKSCC”	the General Rules of HKSCC as may be amended or modified from time to time and where the context so permits, shall include the HKSCC Operational Procedures
“GFA”	gross floor area

[REDACTED]

“Guide” or “Guide for New Listing Applicants”	the Guide for New Listing Applicants as published by the Stock Exchange, as amended from time to time
---	---

DEFINITIONS

“H Share(s)” overseas [REDACTED] foreign Share(s) in the share capital of our Company with a nominal value of RMB0.5 each, which is/are to be [REDACTED] in HK dollars and for which an application has been made for the [REDACTED] of [REDACTED] and permission to [REDACTED] in on the Hong Kong Stock Exchange

[REDACTED]

“H Shareholder(s)” holders of the H Shares

[REDACTED]

“HK\$”, “Hong Kong dollars”, “HK dollars” or “cents” Hong Kong dollars and cents respectively, the lawful currency of Hong Kong

[REDACTED]

“Hong Kong” or “HK” the Hong Kong Special Administrative Region of the People’s Republic of China

DEFINITIONS

“Hong Kong Listing Rules” or “Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited, as amended or supplemented from time to time
---	--

[REDACTED]

“Hong Kong Stock Exchange” or “Stock Exchange”	The Stock Exchange of Hong Kong Limited, a wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited
---	--

[REDACTED]

“IASB”	International Accounting Standards Board
--------	--

“IFRS Accounting Standards”	IFRS Accounting Standards issued by the IASB
-----------------------------	--

“Independent Third Party(ies)”	person(s) or company(ies) and their respective ultimate beneficial owner(s), who/which, to the best of our Directors’ knowledge, information and belief, having made all reasonable enquiries, is/are not our connected persons or associates of our connected persons as defined under the Hong Kong Listing Rules
--------------------------------	---

[REDACTED]

DEFINITIONS

[REDACTED]

“Joint Sponsors” the joint sponsors of the [REDACTED] as named in “Directors and Parties Involved in the [REDACTED]” in this document

“Latest Practicable Date” [July 15], 2026, being the latest practicable date prior to the printing of this document for the purpose of ascertaining certain information contained in this document

[REDACTED]

“Listing Committee” the Listing Committee of the Hong Kong Stock Exchange

[REDACTED]

“Main Board” the stock market (excluding the option market) operated by the Hong Kong Stock Exchange which is independent from and operated in parallel with GEM of the Hong Kong Stock Exchange

“Mr. Li” Mr. Li Yuliang (李雨亮), one of the controlling shareholders of the Company, chairman of the Board, an executive Director and general manager of the Company and the spouse of Ms. Wang

DEFINITIONS

“Mr. Wu”	Mr. Wu Xing (毋興), an executive Director, Chief Financial Officer, Board Secretary, and one of the joint company secretaries of the Company
“Ms. Wang”	Ms. Wang Hongmei (王紅媚), formerly known as Wang Hongmei (王紅梅), an executive Director of the Company and the spouse of Mr. Li
“NEEQ”	the National Equities Exchange and Quotations system (全國中小企業股份轉讓系統), also known as the New Third Board
“NMPA”	the National Medical Products Administration of the PRC (中華人民共和國國家藥品監督管理局) and its predecessor, the China Food and Drug Administration (國家食品藥品監督管理總局)
“Nomination Committee”	the nomination committee of the Board

[REDACTED]

“PCT”	Patent Cooperation Treaty, an international treaty administered by the World Intellectual Property Organization that allows inventors and companies to seek patent protection for their inventions simultaneously in multiple countries through a single international patent application, simplifying the process of securing patent rights across different jurisdictions and providing a standardized procedure for the initial phase of patent filing
“PRC Company Law”	Company Law of the People’s Republic of China (中華人民共和國公司法), as amended, supplemented or otherwise modified from time to time

DEFINITIONS

“PRC Government” or “State”	the central government of the PRC, including all political subdivisions (including provincial, municipal and other regional or local government entities) and its organs or, as the context requires, any of them
“PRC Law”	the laws and regulations of the PRC, without reference to the laws and regulations of Hong Kong, the Macau Special Administrative Region and the relevant regulations of Taiwan region
“PRC Legal Advisor”	Fangda Partners, legal advisor to our Company as to PRC Law
“PRC Securities Law”	the Securities Law of the PRC (《中華人民共和國證券法》), as amended, supplemented or otherwise modified from time to time

[REDACTED]

“document”	this document being issued in connection with the [REDACTED]
“R&D”	research and development
“Regulation S”	Regulation S under the U.S. Securities Act
“Remuneration Committee”	the remuneration committee of the Board
“RMB” or “Renminbi”	Renminbi, the lawful currency of the PRC
“SAFE”	State Administration of Foreign Exchange of the PRC (中華人民共和國外匯管理局)
“SAMR”	State Administration for Market Regulation (國家市場監督管理總局)
“SFC”	the Securities and Futures Commission of Hong Kong

DEFINITIONS

“SFO” or “Securities and Future Ordinance”	the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong), as amended or supplemented from time to time
“Shanghai-Hong Kong Stock Connect”	a securities trading and clearing links program developed by the Hong Kong Stock Exchange, Shanghai Stock Exchange, HKSCC and China Securities Depository and Clearing Corporation Limited for mutual market access between Hong Kong and Shanghai
“Share(s)”	ordinary share(s) in the capital of our Company with nominal value of RMB0.5 each
“Shareholder(s)”	holder(s) of Share(s)
“Sophisticated Investor(s)”	has the meaning ascribed to it under Chapter 2.3 of the Guide
“STA”	State Taxation Administration (中華人民共和國國家稅務總局)
	[REDACTED]
“State Council”	the State Council of the PRC (中華人民共和國國務院)
“Takeovers Code”	the Code on Takeovers and Mergers issued by the SFC, as amended, supplemented or otherwise modified from time to time
“Therapeutics Technology”	PrimeGenX Therapeutics Technology Co., Ltd. (北京普祺醫藥技術有限公司), a limited liability company wholly owned by us and established in the PRC on May 9, 2026
“Track Record Period”	the period comprising the two financial years ended December 31, 2025 and the four months ended April 30, 2026
	[REDACTED]
“U.S.” or “United States”	the United States of America, its territories, its possessions and all areas subject to its jurisdiction
“U.S. Securities Act”	the United States Securities Act of 1933, as amended and supplemented or otherwise modified from time to time, and the rules and regulations promulgated thereunder

DEFINITIONS

“US\$”, “USD” or “U.S. dollars” United States dollars, the lawful currency for the time being of the United States

“%” Per cent

In this document, the terms “associate”, “close associate”, “connected person”, “connected transaction”, “core connected person”, “subsidiary” and “substantial shareholder” shall have the meanings given to such terms in the Hong Kong Listing Rules, unless the context otherwise requires.

If there is any inconsistency between the Chinese names of the entities or enterprises established in the PRC mentioned in this document and their English translations, the Chinese names shall prevail. The English translations of the Chinese names of such PRC entities or enterprises are provided for identification purposes only.